Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses

Frontiers in Pharmacology

Pharmacology

Xiaolin Xiao¹  Jinhao Zeng¹  Xuan He²  Yubing Li³  Xinyu Deng³ 

[1]Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

[2]Department of Pharmacy, Xindu District Shibantan Street Community Healthcare Center, Chengdu, China

[3]School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China

关键词: resveratrol;    nonalcoholic fatty liver disease;    clinical;    preclinical;    integrative evidence;   

DOI  :  10.3389/fphar.2023.1230783

 received in 2023-05-29, accepted in 2023-08-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: Resveratrol, a polyphenol found in various plants, is known for its diverse bioactivities and has been explored in relation to nonalcoholic fatty liver disease (NAFLD). However, no high-quality evidence exists regarding its efficacy.Objective: a meta-analysis was conducted to evaluate the potential efficacy of resveratrol in treating nonalcoholic fatty liver disease by analyzing both preclinical studies and clinical trials.Method: PubMed, Embase and Web of Science were searched for the included literature with the criteria for screening. Quantitative synthesis and meta-analyses were performed by STATA 16.0.Results: Twenty-seven studies were included, and the results indicated that resveratrol effectively improved liver function, reduced fatty liver indicators, and affected other indices in preclinical studies. The effective dosage ranged from 50 mg/kg-200 mg/kg, administered over a period of 4–8 weeks. While there were inconsistencies between clinical trials and preclinical research, both study types revealed that resveratrol significantly reduced tumor necrosis factor-α levels, further supporting its protective effect against nonalcoholic fatty liver disease. Additionally, resveratrol alleviated nonalcoholic fatty liver disease primarily via AMPK/Sirt1 and anti-inflammatory signaling pathways.Conclusion: Current meta-analysis could not consistently verify the efficacy of resveratrol in treating nonalcoholic fatty liver disease, but demonstrated the liver-protective effects on nonalcoholic fatty liver disease. The large-sample scale and single region RCTs were further needed to investigate the efficacy.

【 授权许可】

Unknown   
Copyright © 2023 He, Li, Deng, Xiao and Zeng.